OVID stock icon

Ovid Therapeutics
OVID

$0.78
7.45%
 

About: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.

Employees: 40

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 9 analysts
0
News positive %
of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

2,700% more call options, than puts

Call options by funds: $28K | Put options by funds: $1K

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

22% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 23

5% more funds holding

Funds holding: 76 [Q4 2023] → 80 (+4) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

2.03% less ownership

Funds ownership: 62.43% [Q4 2023] → 60.4% (-2.03%) [Q1 2024]

8% less capital invested

Capital invested by funds: $142M [Q4 2023] → $130M (-$11.8M) [Q1 2024]

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$1.20
54%
upside
Avg. target
$5.63
622%
upside
High target
$9
1,054%
upside

9 analyst ratings

positive
78%
neutral
22%
negative
0%
BTIG
Thomas Shrader
541%upside
$5
Buy
Maintained
18 Jun 2024
B. Riley Securities
Kalpit Patel
285%upside
$3
Buy
Maintained
18 Jun 2024
Citigroup
Yigal Nochomovitz
54%upside
$1.2
Neutral
Maintained
18 Jun 2024
HC Wainwright & Co.
Raghuram Selvaraju
285%upside
$3
Buy
Maintained
18 Jun 2024
HC Wainwright & Co.
Raghuram Selvaraju
1,054%upside
$9
Buy
Reiterated
16 May 2024

Financial journalist opinion

Based on 6 articles about OVID published over the past 30 days